Skip to content

Experimental Alzheimer’s Drug Slows Mental Decline By 27% in Trial Hailed as ‘Most Encouraging to Date’

  • by

American biotech company Biogen announced the results of a phase 3 clinical trial that showed a new Alzheimer’s drug slowed the rate of cognitive decline for early onset patients by 27%. The Alzheimer’s Association (AA) called the robust study of lecanemab, which is a monoclonal antibody designed to clear clumps of amyloid protein from the […]

The post Experimental Alzheimer’s Drug Slows Mental Decline By 27% in Trial Hailed as ‘Most Encouraging to Date’ appeared first on Good News Network.

Leave a Reply

Your email address will not be published. Required fields are marked *